Alain Chebly - Genetic Mutations

Author Information

Alain Chebly is affiliated with the Medical Genetics Unit (UGM) at the Faculty of Medicine, Saint Joseph University, Beirut, Lebanon. His research primarily focuses on the genetics and epigenetics of various cancers, particularly lymphomas and melanomas. His work spans molecular biology, telomere biology, and the impact of genetic modifications on cancer progression and treatment.

Research Contributions

Alain Chebly has made significant contributions to the understanding of cancer genetics and epigenetics. His research includes exploring the role of telomeric repeat-containing RNA (TERRA) in cutaneous T-cell lymphomas, assessing hTERT promoter methylation, and characterizing the genomic profiles of melanomas. Additionally, he has investigated the impact of BRCA mutations in genitourinary and gynecologic tumors and the therapeutic potential of targeting epigenetic modifiers to reduce clonogenic capacities in cancer cells. His studies on the diagnosis and treatment of lymphomas in the context of epigenetics have furthered the field's knowledge on the subject.

Aliases

Alain Chebly is also known by the aliases A. Chebly and Alain Chebly.

Publication and Citation Metrics

Metric	Value
Citation Count	58
H-Index	5
Paper Count	25

Publications:

Telomeric Repeat-Containing RNA (TERRA): A Review of the Literature and First Assessment in Cutaneous T-Cell Lymphomas

DOI: 10.3390/genes13030539

Year: 2022

Exploring hTERT promoter methylation in cutaneous T-cell lymphomas.

DOI: 10.1002/1878-0261.12946

Year: 2021

Comparative genomic characterization of melanoma of known and unknown primary

DOI: 10.1007/s12094-021-02629-2

Year: 2021

Current evidences of BRCA mutations in genitourinary and gynecologic tumors: a scoping review

DOI: 10.21037/pcm-21-47

Year: 2021

An unusual case of chronic lymphocytic leukemia with trisomy 12 and t(14;18) and a favorable response to ibrutinib

DOI: 10.1016/j.lrr.2021.100245

Year: 2021

Targeting Epigenetic Modifiers Can Reduce the Clonogenic Capacities of Sézary Cells

DOI: 10.3389/fonc.2021.775253

Year: 2021

Epigenetic modifiers can alter telomerase expression and clonogenic capacities of Sézary cells

DOI: 10.1016/s0959-8049(21)00640-7

Year: 2021

Pediatric M5 acute myeloid leukemia with MLL-SEPT6 fusion and a favorable outcome

DOI: 10.1016/j.lrr.2021.100277

Year: 2021

Diagnosis and treatment of lymphomas in the era of epigenetics.

DOI: 10.1016/j.blre.2020.100782

Year: 2020

Reliable blood cancer cells' telomere length evaluation by qPCR

DOI: 10.1002/cam4.2816

Year: 2020

How Do Mutations Affect Genetic Coding?

How are CNVs Detected?

Can Insertion Mutations Lead to Diseases?

What Is the Role of Mutations in Evolution?

What is Aneuploidy?

How Are Genetic Diseases Diagnosed?

How do Chemical Mutagens Cause Induced Mutations?

What Are the Benefits of Pharmacogenomics?

Can Genetic Mutations from UV Radiation Be Prevented?

What Types of Genetic Mutations Can CGH Detect?

Partnered Content Networks

Relevant Topics